The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.f

Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

Publications

Martos VP, Vonlanthen B

[Fatal pneumonitis during low-dose methotrexate treatment].

Zeitschrift fur Rheumatologie. 2012;71(1):75-7

Dai MS, Ho CL, Chen YC, Kao WY, Chao TY

Acute respiratory distress syndrome following intrathecal methotrexate administration: a case report and review of literature.

Annals of hematology. 2000;79(12):696-9

Imokawa S, Colby TV, Leslie KO, Helmers RA

Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.

The European respiratory journal. 2000;15(2):373-81

Bhat KS, Anderson KR, Stewart RD

Lung disease associated with methotrexate therapy.

Australian and New Zealand journal of medicine. 1974;4(3):277-80

Lisbona A, Schwartz J, Lachance C, Frank H, Palayew MJ

Methotrexate-induced pulmonary disease.

Journal of the Canadian Association of Radiologists. 1973;24(3):215-20